androstendione | 1192475-82-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: androstendione
• 英文别名: (8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione；androst-4-ene-3,17-dione；4-androsten-3,17-dione；androstenedione；Δ⁴-Androsten-3,17-dion；3,17-Dioxo-androsten-4；10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
• CAS: 1192475-82-3
• 化学式: C₁₉H₂₆O₂
• 分子量: 286.414
• InChiKey: AEMFNILZOJDQLW-UHFFFAOYSA-N

物化性质

• 沸点：
  431.4±45.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  androstendione 在 Aspergillus ochraceus ATCC 18500 作用下， 反应 48.0h， 生成 11α-hydroxy-androst-4-ene-3,17-dione
  参考文献：
  名称：

  5&bgr;-cyano-substituted steroid compounds

  摘要：

  小说5&bgr;-氰基类固醇化合物包括式VII的化合物：其中A—A，B—B，R3，R8和R9如规范中定义。

  公开号：

  US06335441B1

文献信息

• TESTOSTERONE DERIVATIVES WITH A CARBOXYALKYL SUBSTITUTION IN POSITION 3 AND USE THEREOF FOR THE PRODUCTION OF LABELLED STEROIDS FOR DETERMINING THE CONCENTRATION OF TESTOSTERONE IN A BIOLOGICAL SAMPLE
  申请人：BIOMERIEUX

  公开号：US20150299244A1

  公开（公告）日：2015-10-22

  A testosterone derivative of formula (I): where n is an integer in a range of from 1 to 10, and Y represents an activated or ready-to-be-activated group allowing formation of an amide bond with a primary amine of a molecule. Conjugates including the testosterone derivatives and a marker, methods for determining the concentration of testosterone in a biological sample, and methods for preparing the testosterone derivatives are also provided.

  一种公式为(I)的睾酮衍生物：其中n是1到10范围内的整数，Y代表一个活化或准备激活的基团，允许与分子的初级胺形成酰胺键。还提供了包括睾酮衍生物和标记物的共轭物，用于测定生物样本中睾酮浓度的方法，以及制备睾酮衍生物的方法。
• [EN] METHODS FOR PREPARING BILE ACIDS<br/>[FR] PROCÉDÉS DE PRÉPARATION D'ACIDES BILIAIRES
  申请人：MEDYTOX INC

  公开号：WO2019024920A1

  公开（公告）日：2019-02-07

  The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, for example, as described for methods 1, 1A, 1B, 2, 3, 3A, and 4. The method can start with a plant derived steroid as a starting material, such as dehydroepiandrosterone (DHEA) or Acetyl-dehydroepiandrosterone (Ac-DHEA). Also provided are pharmaceutical or cosmetic compositions and uses thereof, which comprise one or more of cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, which is of high purity, for example, free of animal derived impurities.

  本公开提供了制备胆酸、去氧胆酸或烯醇去氧胆酸、其酯或药用或化妆品可接受的盐的方法，以及新颖且有用的合成中间体，例如，如方法1、1A、1B、2、3、3A和4所述。该方法可以以植物源类固醇作为起始物质开始，例如脱氢表雄酮（DHEA）或乙酰脱氢表雄酮（Ac-DHEA）。还提供了包含胆酸、去氧胆酸或烯醇去氧胆酸、其酯或药用或化妆品可接受的盐中的一种或多种的药用或化妆品组合物和用途，其具有高纯度，例如，不含动物来源杂质。
• 立体选择性一步还原甾体骨架中的4-烯-3-酮 为3α-羟基-5β-氢A/B顺式结构的方法
  申请人：复旦大学

  公开号：CN104059118B

  公开（公告）日：2016-12-28

  本发明属有机化学和药物合成领域，涉及甾体骨架4‑烯‑3‑‑酮结构一步还原成A/B顺式的3a‑羟基‑5b‑氢结构的方法。本方法于室温下，在无水乙醇中，以氯化亚铜为催化剂，钠硼氢为还原剂高选择性将4‑AD、ADD及其衍生物的4‑烯‑3‑‑酮结构转化成A/B顺式3a‑羟基‑5b‑氢结构。本方法得到的雄甾‑3a‑羟基‑5b‑氢‑17‑酮产物经X‑衍射确证立体构型，反应条件温和简便，试剂廉价易得，操作方便，重现性好，收率高。本方法为开辟甾醇资源利用，开展探索以非胆酸型甾体原料合成具有A/B顺式结构的熊去氧胆酸、鹅去氧胆酸、去氧胆酸及蜕皮激素等药物的研究奠定了良好基础。
• [EN] METHODS FOR STEREOSELECTIVE REDUCTION<br/>[FR] PROCÉDÉS DE RÉDUCTION STÉRÉOSÉLECTIVE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2009086451A1

  公开（公告）日：2009-07-09

  The invention is directed to a method to reduce a C-C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.

  本发明涉及一种方法，用于还原类固醇化合物的烯酮的C-C双键，以产生β酮产物和α酮产物的混合物，包括在催化剂和取代吡啶的存在下，用氢气处理类固醇化合物在溶剂中的溶液或悬浮液。
• PROCESSES FOR PREPARATION OF 9,11 EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN
  申请人：Ng S. John

  公开号：US20070060746A1

  公开（公告）日：2007-03-15

  Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I wherein: -A-A- represents the group —CHR 4 —CHR 5 — or —CR 4 ═CR 5 — —R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl, lower alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, cyano, aryloxy, R 1 represents an alpha-oriented lower alkoxycarbonyl or hydroxyalkyl radical, —B—B— represents the group —CHR 6 —CHR 7 — or an alpha- or beta-oriented group: where R 6 and R 7 are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, and R 8 and R 9 are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, or R 8 and R 9 together comprise a carbocyclic or heterocyclic ring structure, or R 8 or R 9 together with R 6 or R 7 comprise a carbocyclic or heterocyclic ring structure fused to the pentacyclic D ring.

  提供了多种新颖的反应方案、新颖的过程步骤和新颖的中间体，用于合成环氧甲基瑞酮和其他式I化合物，其中：-A-A-代表基团—CHR4—CHR5—或—CR4═CR5—，——R3、R4和R5分别选择自氢、卤素、羟基、低级烷基、低级烷氧基、羟基烷基、烷氧基烷基、羟基羧基、氰基、芳氧基等组成的群；R1代表α-定向的低级烷氧基羰基或羟基烷基基团，-B-B-代表基团—CHR6—CHR7—或α-或β-定向的基团：其中R6和R7分别选择自氢、卤素、低级烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羧基、烷基、烷氧基羰基、酰氧基烷基、氰基、芳氧基等组成的群；R8和R9分别选择自氢、卤素、低级烷氧基、酰基、羟基烷基、烷氧基烷基、羟基羧基、烷基、烷氧基羰基、酰氧基烷基、氰基、芳氧基，或R8和R9一起构成一个碳环或杂环结构，或R8或R9与R6或R7一起构成一个与五环D环融合的碳环或杂环结构。